Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 10:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 875 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo Multiple Ascending Dose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

NCT06345755
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
VX-407, Placebo, Midazolam
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human Single and Multiple Ascending Dose Study of MT-701

NCT07396909
View directory record Official record
Conditions
Healthy Volunteers
Interventions
MT-701
Drug
Lead sponsor
Mirador Therapeutics, Inc.
Industry
Eligibility
19 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BIIB107 in Healthy Adult Participants

NCT04593121
View directory record Official record
Conditions
Healthy Volunteers
Interventions
BIIB107, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 55 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
3
States / cities
Anaheim, California • Miami, Florida • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 14, 2024 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Pharmacokinetics of SAB-185 in Healthy Participants

NCT04468958
View directory record Official record
Conditions
COVID-19, SARS-CoV2
Interventions
SAB-185, Normal saline
Biological · Other
Lead sponsor
SAb Biotherapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
3
States / cities
Wichita, Kansas • Syracuse, New York • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Sep 4, 2026, 10:35 AM EDT
Recruiting Phase 2 Interventional

A Study to Assess Adverse Events, Change in Disease Activity, and How Oral Emraclidine Moves Through the Body in Adult Participants With Schizophrenia

NCT07145918
View directory record Official record
Conditions
Schizophrenia
Interventions
Emraclidine, Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
268 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
7
States / cities
Little Rock, Arkansas • Garden Grove, California • Glendale, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2026 · Synced Sep 4, 2026, 10:35 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Study of BMF-650 in Otherwise Healthy Overweight or Obese Adult Participants

NCT07223216
View directory record Official record
Conditions
Obesity
Interventions
BMF-650
Drug
Lead sponsor
Biomea Fusion Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Randomized, Double Blind Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986166 in Healthy Subjects

NCT02790125
View directory record Official record
Conditions
Healthy
Interventions
BMS-986166, Placebo matching BMS-986166
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2017 · Synced Sep 4, 2026, 10:35 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of SBS-147 in Healthy Adults

NCT07335913
View directory record Official record
Conditions
Pain Acute, Pain
Interventions
SBS-147, Placebo
Drug
Lead sponsor
Sparian Biosciences, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Sep 4, 2026, 10:35 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics of UV-4B Solution Administered Orally as Multiple Ascending Doses to Healthy Subjects

NCT02696291
View directory record Official record
Conditions
Viral Infection
Interventions
UV-4B 30 mg oral solution, UV-4B 75 mg oral solution, UV-4B 150 mg oral solution, UV-4B X mg (dose to be determined) oral solution, UV-4B Y mg (dose to be determined) oral solution, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 17, 2024 · Synced Sep 4, 2026, 10:35 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

NCT07024602
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ASC50 tablets or matching placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study to Investigate Safety of KBP-7072 in Healthy Subjects

NCT04532957
View directory record Official record
Conditions
Healthy
Interventions
KBP-7072, Placebo
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Sub-Lingual Dexmedetomidine in Agitation Associated With Schizophrenia

NCT04010305
View directory record Official record
Conditions
Agitation, Schizophrenia
Interventions
Sublingual film containing BXCL501 (Dexmedetomidine), Placebo film
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
12
States / cities
Little Rock, Arkansas • Cerritos, California • Lemon Grove, California + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Multiple Ascending Dose Trial of CVL-231 in Subjects With Schizophrenia

NCT04136873
View directory record Official record
Conditions
Schizophrenia
Interventions
CVL-231, Matching Placebo
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Bentonville, Arkansas • Little Rock, Arkansas • Lemon Grove, California + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Multiple Ascending Dose Study of COR388

NCT03418688
View directory record Official record
Conditions
Alzheimer Disease
Interventions
COR388, Placebo
Drug
Lead sponsor
Cortexyme Inc.
Industry
Eligibility
55 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
3
States / cities
San Diego, California • Orlando, Florida • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple-Dose Study of VGX-1027 in Healthy Subjects

NCT00760396
View directory record Official record
Conditions
Healthy
Interventions
VGX-1027
Drug
Lead sponsor
VGX Pharmaceuticals, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS

NCT01764737
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
VX15/2503, Placebo
Drug
Lead sponsor
Vaccinex Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Cullman, Alabama • Aurora, Colorado • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2015 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults

NCT06394167
View directory record Official record
Conditions
Pain
Interventions
VX-993, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 4, 2026, 10:35 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease

NCT06565195
View directory record Official record
Conditions
Parkinson's Disease
Interventions
LY3962681, Placebo (aCSF)
Drug · Other
Lead sponsor
Prevail Therapeutics
Industry
Eligibility
30 Years to 80 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
7
States / cities
Englewood, Colorado • New Haven, Connecticut • Naples, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects

NCT03954600
View directory record Official record
Conditions
Healthy Volunteers
Interventions
NPT520-34 (125 mg), Placebos (125 mg)
Drug
Lead sponsor
Neuropore Therapies Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of LY3549492 in Healthy Participants

NCT04758234
View directory record Official record
Conditions
Healthy
Interventions
LY3549492, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 8, 2022 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO5093151 in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).

NCT02622334
View directory record Official record
Conditions
Glaucoma
Interventions
Latanoprost, Placebo, RO5093151
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
6
States / cities
Artesia, California • Aurora, Colorado • Morrow, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional

A Study of Single and Multiple Ascending Doses of VIB1116 in Rheumatic Diseases

NCT04948099
View directory record Official record
Conditions
Dendritic Cell -Mediated Rheumatic Diseases
Interventions
VIB1116, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
8
States / cities
Anniston, Alabama • Clearwater, Florida • Jacksonville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2024 · Synced Sep 4, 2026, 10:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of BIA 9-1067 in Healthy Japanese and Caucasian Subjects

NCT01520987
View directory record Official record
Conditions
Parkinson Disease
Interventions
BIA 9-1067, Placebo
Drug
Lead sponsor
Bial - Portela C S.A.
Industry
Eligibility
18 Years to 65 Years
Enrollment
105 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 19, 2016 · Synced Sep 4, 2026, 10:35 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Single Ascending Dose and Multiple Ascending Dose Study of AVR-48

NCT06847698
View directory record Official record
Conditions
Safety Issues, Tolerability, Pharmacokinetics, Pharmacodynamics
Interventions
AVR-48, Placebo
Drug
Lead sponsor
AyuVis Research, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 5, 2025 · Synced Sep 4, 2026, 10:35 AM EDT